| 杨海松,毛大华,张世泳,周福林,杨良权.紫杉醇联合表阿霉素新辅助化疗治疗三阴性乳腺癌的临床疗效评价及其对Ki-67、p53、P-gp和GST-π的影响[J].,2017,17(22):4281-4284 |
| 紫杉醇联合表阿霉素新辅助化疗治疗三阴性乳腺癌的临床疗效评价及其对Ki-67、p53、P-gp和GST-π的影响 |
| Clinical Evaluation of Paclitaxel Combined with Epirubicin Neoadjuvant Chemotherapy in Treatment of Triple Negative Breast Cancer and Its Effect on Expressions of Ki-67, p53, P-gp and GST-π |
| 投稿时间：2017-01-25 修订日期：2017-02-22 |
| DOI：10.13241/j.cnki.pmb.2017.22.018 |
| 中文关键词: 紫杉醇 表阿霉素 三阴性乳腺癌 |
| 英文关键词: Paclitaxel Epirubicin Triple negative breast cancer |
| 基金项目:贵州省科技厅基金项目(黔科合J字[2012]2057号) |
|
| 摘要点击次数: 281 |
| 全文下载次数: 194 |
| 中文摘要: |
| 摘要 目的：研究紫杉醇联合表阿霉素新辅助化疗治疗三阴性乳腺癌的临床疗效及对Ki-67、p53、P-糖蛋白(P-gp)和谷胱甘肽转移酶(GST-π)的影响。方法：选取2010年6月～2012年6月我院收治的84例三阴乳腺癌患者，根据患者入院顺序分为观察组和对照组，42例每组。对照组使用表阿霉素联合环磷酰胺完成化疗，观察组使用紫杉醇联合表阿霉素完成新辅助化疗。比较两组患者临床疗效，治疗前后Ki-67、p53、P-gp和GST-π的表达情况。结果：治疗后，观察组总的缓解率显著高于对照组[76.19%(32/42)比45.24%(19/42)](P<0.05)。化疗前，两组患者Ki-67、p53、P-gp和GST-π阳性表达率比较无统计学意义(P>0.05)；化疗后，观察组患者的Ki-67、p53、P-gp和GST-π阳性表达率较化疗前显著降低(P<0.05)，但对照组的Ki-67、p53、P-gp和GST-π阳性表达率和化疗前相比无明显变化(P>0.05)，观察组的Ki-67、p53、P-gp和GST-π阳性表达率显著低于对照组(P<0.05)。观察组和对照组的不良反应率比较差异无统计学意义(P>0.05)。结论：紫杉醇联合表阿霉素新辅助化疗治疗三阴性乳腺癌的疗效确切，其能有效降低Ki-67、p53、P-gp和GST-π的表达。 |
| 英文摘要: |
| ABSTRACT Objective: To evaluate the clinical efficacy of paclitaxel combined with epirubicin neoadjuvant chemotherapy in the treatment of triple negative breast cancer and the effect on the Ki-67, p53, P-glycoprotein (P-gp) and glutathione transferase (GST-π). Methods: 84 patients with triple - negative breast cancer admitted in our hospital from June 2010 to June 2012 were selected and divided into the observation group and the control group according to the order of admission. The control group was treated with epirubicin, and cyclophosphamide. The observation group was given paclitaxel neoadjuvant chemotherapy combined with epirubicin. The clinical efficacy, expressions of Ki-67, p53, P-gp and GST-π were compared between the two groups. Results: After treatment, the total remission rate of observation group was significantly higher than that of the control group [76.19%(32/42) vs 45.24%(19/42)] (P <0.05). Before chemotherapy, the positive expression rates of Ki-67, p53, P-gp and GST-π in the two groups showed no statistical difference(P> 0.05). After chemotherapy, the positive expression rates of Ki-67, p53, P-gp and GST-π in the observation group were significantly lower than those of the control group (P<0.05), but the positive expression rates of Ki-67, p53, P-gp and GST-π in the control group had no significant difference compared with those before chemotherapy(P>0.05). The positive expression rates of Ki-67, p53, P-gp and GST-π in the observation group were significantly lower than those of the control group (P <0.05). There was no significant difference in the incidence of adverse reaction rate between the observation group and the control group (P> 0.05). Conclusion: Paclitaxel combined with Epirubicin neoadjuvant chemotherapy could effectively reduce the expression of Ki-67, p53, P-gp and GST-π in triple-negative breast cancer with exact clinical efficacy. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
